This article is more than 5 years old. Information may no longer be current.
Triamcinolone injection at end of retinal surgery may be alternative to steroid drops
Click Here to Manage Email Alerts
VANCOUVER, British Columbia — A single subconjunctival 4 mg triamcinolone injection after retinal surgery had comparable IOP and inflammatory outcomes as a subconjunctival 1 mg dexamethasone injection and a 4- to 6-week steroid taper, according to a speaker here.
“It is reasonable for retinal surgeons to consider freeing their patients from the traditional drop taper and instead using a single subconjunctival injection [of triamcinolone] at the end of the case,” Elizabeth A. Atchison, MD, said at the American Society of Retina Specialists annual meeting.
The retrospective case series included an intervention group of 167 eyes of 154 patients who received a single 4 mg injection of triamcinolone acetonide at the end of surgery and a control group of 110 eyes of 103 patients who received dexamethasone 1 mg at the end of surgery and a traditional topical steroid taper over a 4- to 6-week period, Atchison said.
During the first 3 months postop, no statistically significant differences in IOP were found between the two groups. Atchison said 16% of patients in the intervention group experienced an IOP of 30 mm Hg or greater and 20% of patients experienced an IOP increase of 10 mm Hg or greater from their baseline at 3 months postop compared with 12% and 14% of patients, respectively, in the control group. – by Robert Linnehan
Reference:
Atchison EA. Single intraoperative subconjunctival triamcinolone acetonide injection versus 4-6 week topical steroid taper following vitreoretinal surgery. Presented at: American Society of Retina Specialists annual meeting; July 20-25, 2018; Vancouver, British Columbia.
Disclosure: Atchison reports no relevant financial disclosures.